SMO Expression in Colorectal Cancer: Associations with Clinical, Pathological, and Molecular Features
Document Type
Journal Article
Publication Date
1-1-2014
Journal
Annals of Surgical Oncology
Volume
21
Issue
13
DOI
10.1245/s10434-014-3888-y
Abstract
© 2014, Society of Surgical Oncology. Background: Smoothened, frizzled family receptor (SMO) is an important component of the hedgehog signaling pathway, which has been implicated in various human carcinomas. However, clinical, molecular, and prognostic associations of SMO expression in colorectal cancer remain unclear.Methods: Using a database of 735 colon and rectal cancers in the Nurse’s Health Study and the Health Professionals Follow-up Study, we examined the relationship of tumor SMO expression (assessed by immunohistochemistry) to prognosis, and to clinical, pathological, and tumor molecular features, including mutations of KRAS,BRAF, and PIK3CA, microsatellite instability, CpG island methylator phenotype (CIMP), LINE-1 methylation, and expression of phosphorylated AKT and CTNNB1.Results: SMO expression was detected in 370 tumors (50 %). In multivariate logistic regression analysis, SMO expression was independently inversely associated with phosphorylated AKT expression [odds ratio (OR) 0.48; 95 % confidence interval (CI) 0.34–0.67] and CTNNB1 nuclear localization (OR 0.48; 95 % CI 0.35–0.67). SMO expression was not significantly associated with colorectal cancer-specific or overall survival. However, in CIMP-high tumors, but not CIMP-low/0 tumors, SMO expression was significantly associated with better colorectal cancer-specific survival (log-rank P = 0.012; multivariate hazard ratio, 0.36; 95 % CI 0.13–0.95; Pinteraction = 0.035, for SMO and CIMP status).Conclusions: Our data reveal novel potential associations between the hedgehog, the WNT/CTNNB1, and the PI3K (phosphatidylinositol-4,5-bisphosphonate 3-kinase)/AKT pathways, supporting pivotal roles of SMO and hedgehog signaling in pathway networking. SMO expression in colorectal cancer may interact with tumor CIMP status to affect patient prognosis, although confirmation by future studies is needed.
APA Citation
Li, T., Liao, X., Lochhead, P., Morikawa, T., Yamauchi, M., Nishihara, R., Inamura, K., Kim, S., Mima, K., Sukawa, Y., Kuchiba, A., Imamura, Y., Baba, Y., Shima, K., Meyerhardt, J., Chan, A., Fuchs, C., Ogino, S., & Qian, Z. (2014). SMO Expression in Colorectal Cancer: Associations with Clinical, Pathological, and Molecular Features. Annals of Surgical Oncology, 21 (13). http://dx.doi.org/10.1245/s10434-014-3888-y